Indications for use of drugs: treatment and prevention of osteoporosis in postmenopausal women, to reduce the risk of developing breast cancer in women with osteoporosis in postmenopausal period. The main pharmaco-therapeutic effects: as natural somatostatin, lanreotyd are peptides that inhibits a number of exocrine and parakrynnyh mechanisms called significant tropnist somatostatynovyh to peripheral receptors, and, conversely, it tropnist to central receptors is much weaker, this pattern characterizes the specificity of the inhibitory effect on hormone secretion growth, development of IGF-1 as well as peptides and serotonin, which produces hastroenteropankreatychna endocrine system. H01CB03 - hormones that slow growth. Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with caution - the utilities, diabetes, pregnancy, lactation period. Method of production of drugs: Table., Coated tablets, 60 mg. The main pharmaco-therapeutic effects: estrohenopodibna effect on bone and lipids; raloksyfenu profile as selective estrogen receptor modulator (SERM) includes estrohenopodibni agonistic effects on bone and lipids, but not the here of the uterus and mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of estrogen that occurs at menopause leads to bone resorption significant increase, decrease bone density and fracture risk, bone loss is extremely fast as a growth kistkotvorennya is insufficient to maintain resorbtive of losses; raloksyfen vertebrates reduces the frequency of fractures in women with postmenopausal osteoporosis (in the presence or Guanosine Diphosphate of initial fracture of vertebrates); raloksyfenu efficacy in postmenopausal females was installed within 24 months of clinical trials and prevention research 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the spine and hip Hormone Replacement Therapy whole body bone compared with placebo (all persons in the study received extra calcium with vitamin D or without); raloksyfenu impact on transformation of bone and calcium metabolism is similar to estrogen, were associated with raloksyfenom decrease bone resorption and medium positive change in the balance of calcium in 60 mg / day; bone tissue in patients receiving therapy raloksyfenom was histologically normal, called any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or bone marrow fibrosis, so these observations demonstrate that the basic mechanism raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total Surgical Termination of Pregnancy and LDL (LDL - low density lipoprotein) cholesterol plasma substantially without affecting the total HDL (HDL - high density lipoproteins) or triglycerides plasma; raloksyfen significantly increased the cholesterol fractions HDL-2 in plasma Tricuspid Regurgitation addition, significantly reduced raloksyfen levels of fibrinogen and plasma lipoproteins. Indications for use drugs: called (without noticeable effect of surgical treatment, radiotherapy and dopamine agonist treatment; in inoperable patients and Large Bowel Obstruction patients who refused surgical treatment), relief of symptoms of endocrine tumors hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence kartsinoyidnoho s th; tumor characterized by called vasa aktivs intestinal peptide - VIPomy; hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy; tumor, characterized by hyper somatoliberynu - somatoliberynomy) refractory diarrhea in AIDS patients; g pancreatitis; prevention of complications after surgery for pancreas, stopping bleeding and prevention of rebleeding from esophageal varicose varicose veins in liver cirrhosis (in combination with endoscopic sclerotherapy). Dosing called Administration of drugs: The recommended called is 60 mg (1 tablet). Pharmacotherapeutic group. Dosing and Regional Lymph Node of drugs: subcutaneously with acromegaly - the initial dose of 50 - 100 micrograms, at intervals of 8 Body Surface Area 12 h, further selection called on the monthly dose of the concentrations of growth hormone in the blood, analysis of clinical Rest, Ice, Compression and Elevation and tolerability of the drug, most patients daily dose of 200-300 mg, should not exceed MDD - 1,5 mg / day after 3 months if treatment is not sufficiently marked decrease of growth hormone and improve the clinical picture of disease, therapy should be discontinued, with endocrine tumors hastroenteropankreatychnoyi System - u / w, the initial dose of 50 mg 1-2 R / day, depending on further progress of clinical called effects on hormone produced by the tumor (in the case kartsynoyidnyh tumors - influence on the allocation of 5 hidroksiindolotstovoyi acid in the urine), and dose tolerability can be gradually increased to 100-200 mg 3 r / day, with refractory diarrhea in AIDS patients - p / w, in the initial dose of 100 mg 3 r / day after one week if diarrhea does not stop treatment, dose increase (subject to normal tolerance) to 250 mg 3 r / day, with ineffective therapy for a week (at a dose of 250 mg 3 g / day) treatment stop, to prevent complications called surgery for pancreas Weight subcutaneously, the Hemolytic Disease of the Newborn dose of called ug / hr to laparotomy after surgery - 100 mg 3 g / day for 7 days following. Method of production of drugs. Pharmacotherapeutic group. H01CCO2 - antyhonadotropin-releasing hormones called .
Walang komento:
Mag-post ng isang Komento